List of works - Jun Wang

"Click" synthesis of small molecule probes for activity-based fingerprinting of matrix metalloproteases

scientific article published on 15 August 2006

2D IR spectroscopy reveals the role of water in the binding of channel-blocking drugs to the influenza M2 channel.

scientific article

3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.

scientific article published on 15 November 2013

A Novel Capsid Binding Inhibitor Displays Potent Antiviral Activity against Enterovirus D68

scientific article published on 18 September 2019

Activity-based high-throughput profiling of metalloprotease inhibitors using small molecule microarrays

scientific article published on 04 January 2006

Affinity of Rimantadine Enantiomers against Influenza A/M2 Protein Revisited

scientific article published on 27 January 2017

An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses

scientific article published on 10 January 2017

An assay suitable for high throughput screening of anti-influenza drugs

scientific article

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

scientific article published on 21 April 2020

Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture

scientific article published on 01 November 2020

Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral.

scientific article published on 8 September 2017

De novo design of self-assembling foldamers that inhibit heparin-protein interactions

scientific article published on 11 February 2014

Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus

scientific article

Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model

scientific article published on 28 March 2024

Detection of drug-induced conformational change of a transmembrane protein in lipid bilayers using site-directed spin labeling

scientific article published on 19 November 2012

Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses

scientific article published on 11 June 2018

Discovery of Influenza Polymerase PA-PB1 Interaction Inhibitors Using an In Vitro Split-Luciferase Complementation-Based Assay

scientific article published on 21 November 2019

Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68)

scientific article published on 03 April 2019

Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay

scientific article published on 18 June 2021

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19

scientific article published on 13 September 2020

Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance

scientific article published on 28 July 2016

Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses

scientific article published on August 2017

Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus

scientific article

Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus

scientific article

Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor

scientific article published on 11 April 2022

Drug-induced conformational and dynamical changes of the S31N mutant of the influenza M2 proton channel investigated by solid-state NMR.

scientific article

Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors

scientific article published on 09 October 2020

Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors

scientific article published on 16 September 2020

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

scientific article published on 23 April 2021

Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki-Miyaura Cross-Coupling Reaction

scientific article published on 9 February 2017

Exploring Organosilane Amines as Potent Inhibitors and Structural Probes of Influenza A Virus M2 Proton Channel ⬇️

scientific article published on August 12, 2011

Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance

scientific article published on 15 March 2018

Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus

scientific article published on April 2011

Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus

scientific article published on 05 April 2011

Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel.

scientific article

Focusing on the influenza virus polymerase complex: recent progress in drug discovery and assay development

article

Functional studies reveal the similarities and differences between AM2 and BM2 proton channels from influenza viruses.

scientific article published on 26 October 2017

Identification of NMS-873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses

scientific article published on 28 March 2019

In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses.

scientific article published on 17 January 2018

Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target.

scientific article published on 24 February 2017

Influenza virus A M2 protein generates negative Gaussian membrane curvature necessary for budding and scission.

scientific article published on 06 September 2013

Inhibitor fingerprinting of matrix metalloproteases using a combinatorial peptide hydroxamate library

scientific article

Inhibitors of the M2 Proton Channel Engage and Disrupt Transmembrane Networks of Hydrogen-Bonded Waters

scientific article published on 12 September 2018

Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay

scientific article

Inhibitors targeting the influenza virus hemagglutinin.

scientific article

Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor

scientific article published on 12 May 2022

Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.

scientific article published on 6 July 2016

Photoinduced Electron Transfer and Fluorophore Motion as a Probe of the Conformational Dynamics of Membrane Proteins: Application to the Influenza A M2 Proton Channel ⬇️

scientific article published on March 14, 2011

Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers.

scientific article

Protein and small molecule microarrays: powerful tools for high-throughput proteomics

scientific article

Proton and cation transport activity of the M2 proton channel from influenza A virus

scientific article

Protonation equilibria and pore-opening structure of the dual-histidine influenza B virus M2 transmembrane proton channel from solid-state NMR.

scientific article published on 11 September 2017

Quantitative inhibitor fingerprinting of metalloproteases using small molecule microarrays

scientific article

Rapid assembly of matrix metalloprotease inhibitors using click chemistry.

scientific article published in August 2006

Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir

scientific article published on 09 June 2021

Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses.

scientific article

Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus

scientific article published on 18 April 2017

Solid-State NMR Investigation of the Conformation, Proton Conduction, and Hydration of the Influenza B Virus M2 Transmembrane Proton Channel

scientific article (publication date: 6 July 2016)

Solid-supported membrane technology for the investigation of the influenza A virus M2 channel activity

scientific article

Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy

scientific article published on 7 March 2011

Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus.

scientific article published on 17 January 2011

Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L

scientific article published on 06 November 2020

Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus ⬇️

scientific article published on January 9, 2013

Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers

scientific article

Symmetric dimeric adamantanes for exploring the structure of two viroporins: influenza virus M2 and hepatitis C virus p7.

scientific article

The L46P mutant confers a novel allosteric mechanism of resistance toward the influenza A virus M2 S31N proton channel blockers

scientific article published on 07 June 2019

The antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor

scientific article

Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.

scientific article

Validating Enterovirus D68-2Apro as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68-2Apro Inhibitor

scientific article published on 21 March 2019

X-ray Crystal Structure of the Influenza A M2 Proton Channel S31N Mutant in Two Conformational States: An Open and Shut Case

scientific article published on 11 July 2019

X-ray Crystal Structures of the Influenza M2 Proton Channel Drug-Resistant V27A Mutant Bound to a Spiro-Adamantyl Amine Inhibitor Reveal the Mechanism of Adamantane Resistance

scientific article published on 13 January 2020

List of works by Jun Wang

"Click" synthesis of small molecule probes for activity-based fingerprinting of matrix metalloproteases

2D IR spectroscopy reveals the role of water in the binding of channel-blocking drugs to the influenza M2 channel.

3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.

A Novel Capsid Binding Inhibitor Displays Potent Antiviral Activity against Enterovirus D68

Activity-based high-throughput profiling of metalloprotease inhibitors using small molecule microarrays

Affinity of Rimantadine Enantiomers against Influenza A/M2 Protein Revisited

An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses

An assay suitable for high throughput screening of anti-influenza drugs

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture

Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral.

De novo design of self-assembling foldamers that inhibit heparin-protein interactions

Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus

Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model

Detection of drug-induced conformational change of a transmembrane protein in lipid bilayers using site-directed spin labeling

Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses

Discovery of Influenza Polymerase PA-PB1 Interaction Inhibitors Using an In Vitro Split-Luciferase Complementation-Based Assay

Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68)

Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19

Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance

Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses

Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus

Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus

Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor

Drug-induced conformational and dynamical changes of the S31N mutant of the influenza M2 proton channel investigated by solid-state NMR.

Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors

Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki-Miyaura Cross-Coupling Reaction

Exploring Organosilane Amines as Potent Inhibitors and Structural Probes of Influenza A Virus M2 Proton Channel ⬇️

Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance

Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus

Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus

Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel.

Focusing on the influenza virus polymerase complex: recent progress in drug discovery and assay development

Functional studies reveal the similarities and differences between AM2 and BM2 proton channels from influenza viruses.

Identification of NMS-873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses

In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses.

Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target.

Influenza virus A M2 protein generates negative Gaussian membrane curvature necessary for budding and scission.

Inhibitor fingerprinting of matrix metalloproteases using a combinatorial peptide hydroxamate library

Inhibitors of the M2 Proton Channel Engage and Disrupt Transmembrane Networks of Hydrogen-Bonded Waters

Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay

Inhibitors targeting the influenza virus hemagglutinin.

Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor

Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.

Photoinduced Electron Transfer and Fluorophore Motion as a Probe of the Conformational Dynamics of Membrane Proteins: Application to the Influenza A M2 Proton Channel ⬇️

Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers.

Protein and small molecule microarrays: powerful tools for high-throughput proteomics

Proton and cation transport activity of the M2 proton channel from influenza A virus

Protonation equilibria and pore-opening structure of the dual-histidine influenza B virus M2 transmembrane proton channel from solid-state NMR.

Quantitative inhibitor fingerprinting of metalloproteases using small molecule microarrays

Rapid assembly of matrix metalloprotease inhibitors using click chemistry.

Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir

Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses.

Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus

Solid-State NMR Investigation of the Conformation, Proton Conduction, and Hydration of the Influenza B Virus M2 Transmembrane Proton Channel

Solid-supported membrane technology for the investigation of the influenza A virus M2 channel activity

Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy

Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus.

Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L

Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus ⬇️

Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers

Symmetric dimeric adamantanes for exploring the structure of two viroporins: influenza virus M2 and hepatitis C virus p7.

The L46P mutant confers a novel allosteric mechanism of resistance toward the influenza A virus M2 S31N proton channel blockers

The antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor

Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.

Validating Enterovirus D68-2Apro as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68-2Apro Inhibitor

X-ray Crystal Structure of the Influenza A M2 Proton Channel S31N Mutant in Two Conformational States: An Open and Shut Case

X-ray Crystal Structures of the Influenza M2 Proton Channel Drug-Resistant V27A Mutant Bound to a Spiro-Adamantyl Amine Inhibitor Reveal the Mechanism of Adamantane Resistance